Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04050280
Title CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Maryland, Baltimore

acute myeloid leukemia


Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin

Gemtuzumab ozogamicin

Cladribine + Cytarabine + Filgrastim

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.